US2009111870A1PendingUtilityA1

Angelicae Sinensis Extracts Useful for Treatment of Cancers

53
Assignee: BUDDHIST TZU CHI GENERAL HOSPIPriority: Oct 8, 2004Filed: Oct 29, 2008Published: Apr 30, 2009
Est. expiryOct 8, 2024(expired)· nominal 20-yr term from priority
A61P 35/02A61P 43/00A61P 35/00A61K 31/34A61K 36/232
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

An acetone extract, chloroform extract or hexane extract of Angelicae sinensis and/or the active components purified therefrom, such as n-butylidenephthalide, are administered alone or in combination with one or more chemotherapy drugs and are effective in treating cancers.

Claims

exact text as granted — not AI-modified
1 . A pharmaceutical composition for inhibiting proliferation of cancer cells, comprising an active ingredient consisting essentially of n-butylidenephthalide alone. 
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein the cancer cells is selected from the group consisting of human malignant glioblastoma, colorectal, leukemia, neuroblastoma, hepatoma, breast, ovarian and lung cancer. 
     
     
         3 . A pharmaceutical composition for inhibiting proliferation of cancer cells, comprising an active ingredient consisting essentially of n-butylidenephthalide alone; and one or more chemotherapy drugs. 
     
     
         4 . The pharmaceutical composition of  claim 3 , wherein the cancer cells is selected from the group consisting of human malignant glioblastoma, colorectal, leukemia, neuroblastoma, hepatoma, breast, ovarian and lung cancer. 
     
     
         5 . A method for inhibiting cancer cells proliferation and migration comprising administering an active ingredient consisting essentially of n-butylidenephthalide alone to the cancer cell. 
     
     
         6 . The method of  claim 5 , wherein the cancer cells are selected from the group consisting of human malignant glioblastoma, colorectal, leukemia, neuroblastoma, hepatoma, breast, ovarian and lung cancer. 
     
     
         7 . The method of  claim 5 , wherein the n-butylidenephthalide is administered via an oral, parenteral, intravenous (iv), intraperitoneal (ip), intramuscular (im), subcutaneous (sc), pulmonary, transdermal, buccal, nasal, sublingual, ocular, rectal or vaginal route. 
     
     
         8 . The method of  claim 5 , wherein the n-butylidenephthalide is administered via an oral, parenteral, or intravenous route.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.